New drug shows promise for rare lung complication after transplant

NCT ID NCT03674047

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 18, 2026 · Updated 25 times

Summary

This study tests the drug ruxolitinib for people who developed bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The goal is to see if the drug can improve lung function or prevent further decline. About 50 participants will take ruxolitinib for 3 months, and doctors will measure changes in their breathing tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OTHER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.

OTHER CANCER